Browse comprehensive guides on diseases — evidence-based content reviewed by MyMedicPlus Medical Review Board.
206 entries
206 results
Clinical guide to pediatric oncology. Covers the most common childhood cancers — ALL, brain tumors, neuroblastoma, Wilms tumor, lymphomas — risk-stratified protocols, CAR-T cell therapy for relapsed ALL, and late effects management.
Clinical guide to pediatric visual pathway glioma (optic pathway glioma). Covers NF1 association, BRAF-KIAA1549 fusion, carboplatin-vincristine chemotherapy, selumetinib (FIREFLY-1 trial), and ophthalmic surveillance protocols.
Clinical guide to cholangiocarcinoma. Covers intrahepatic, perihilar (Klatskin), and distal subtypes; FGFR2 fusion; IDH1 mutation; TOPAZ-1 trial (gemcitabine-cisplatin-durvalumab); pemigatinib; ivosidenib; and liver transplant criteria.
Clinical guide to chordoma — rare malignant bone tumor of notochordal origin. Covers sacral, clival, and mobile spine variants; brachyury (T gene) biology; en bloc surgical resection; proton beam and carbon ion radiotherapy; and imatinib-based systemic therapy.
Clinical guide to CLL. Covers iwCLL diagnostic criteria, Rai/Binet staging, del(17p)/TP53 risk stratification, IGHV mutation status, ibrutinib/acalabrutinib BTK inhibitors, venetoclax-obinutuzumab, MRD-negative remission, and Richter's transformation.
Clinical guide to CML. Covers BCR-ABL1 Philadelphia chromosome biology, TKI therapy (imatinib, dasatinib, nilotinib, bosutinib, ponatinib, asciminib), ELN 2020 response milestones, treatment-free remission (TFR), and blast phase management.
Comprehensive guide to CML and the Philadelphia chromosome (BCR-ABL1). Covers TKI therapy (imatinib, dasatinib, nilotinib, asciminib STAMP inhibitor), ELN 2020 molecular milestones, treatment-free remission, and near-normal life expectancy outcomes.
Clinical guide to chronic myeloproliferative neoplasms (MPNs) — including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Covers JAK2 V617F mutation, thrombosis risk, hydroxyurea, ruxolitinib, and allogeneic SCT.
Clinical guide to myeloproliferative neoplasms (PV, ET, MF). Covers JAK2 V617F, CALR, MPL mutations, WHO 2022 diagnostic criteria, ruxolitinib, fedratinib, pacritinib, hydroxyurea, thrombosis risk, and allogeneic SCT for high-risk myelofibrosis.
Expert guide to CNS embryonal tumors including medulloblastoma. Covers WHO 2021 molecular subgroups (WNT, SHH, Group 3, Group 4), craniospinal irradiation, VCR/CCNU/cisplatin chemotherapy, and long-term survivor care.
Clinical guide to CNS embryonal tumors including medulloblastoma, AT/RT, and ETMR. Covers WHO 2021 molecular subgroups (WNT, SHH, Group 3, Group 4), SMARCB1, C19MC, craniospinal irradiation, and risk-stratified chemotherapy protocols.
Comprehensive guide to congenital aortic coarctation. Covers duct-dependent neonatal presentation, bicuspid aortic valve and Turner syndrome associations, surgical repair versus balloon stent treatment, lifelong hypertension management, and AHA/ACC 2018 surveillance guidelines.
Our patient support team can guide you to the best hospitals, doctors, and treatments based on your specific needs.
Medical Disclaimer: The information on MyMedicPlus is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this site.